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Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach 
Lewei (Allison) Lin, (Sponsored by: Robert Rosenheck), Department of Psychiatry, Yale 
University School of Medicine, New Haven, CT  
HYPOTHESIS/AIMS: Apply health state analysis to a large clinical trial dataset of 
patients with schizophrenia to provide added insights into clinical and quality of life 
characteristics.  We also evaluated the hypothesis that there is no difference in the distribution of 
health states of patients across several antipsychotic medications. METHODS: This study was a 
secondary analysis of data from the CATIE trial, a multi-site double blind clinical trial of 
antipsychotic treatments for schizophrenia. We applied K-means clustering to the CATIE data, 
creating discrete clusters with symptom and side effect characteristics that were then validated 
using a panel of quality of life measures. A comparison was made across medications for 
differences in cluster distributions at baseline and 6 months. RESULTS: 1049 patients from the 
CATIE trial dataset were included for initial cluster analysis.  By examining cluster profile plots, 
it was determined that 5 was the optimum number of health states. Using intent to treat, the model 
was applied to compare 6-month outcomes for patients on perphenazine, olanzapine, risperidone 
and quetiapine. Chi square tests of independence showed significant difference (p=0.0090) in the 
distribution of patients across health states for the 4 medications at 6 months. Chi squared 
pairwise comparisons were significant for only perphenazine vs. risperidone  (p = 0.012 < α of 
0.025 with Hochberg correction) and for olanzapine vs. risperidone  (p= 0.0010 < α of 0.05) but 
not for any other pairs. At baseline, almost 20% of patients were in the worst health state 
(HS+Dp+Ak), but decreased at 6 months, with the greatest decreases in the pherphenazine (9.2% 
decrease) and olanzapine (11.1%) groups compared to risperidone (4.7%) and quetiapine (6.7%). 
There was a large increase in the best health state (LS+LSE) for patients taking perphenazine 
(15.0%), olanzapine (18.5%) and quetiapine (12.0%) but less for patients taking risperidone 
(4.5%).  CONCLUSION: This study demonstrated health state analysis is a useful tool that 
provides information on the overall clinical state of patients and can potentially be used to help 








I would like to extend sincere thanks to my advisor, Dr. Robert Rosenheck for his 
patience and dedication to this project.  Thank you for the guidance, the rapid fire e-
mails, and the many conversations regarding this paper and the field in general.  I greatly 
appreciated the opportunity to work with you and hope we continue to have opportunities 
in the future.   
 
I would also like to thank Catherine Sugar, the Director of the Semel Institute 
Statistics Core and Assistant Professor of Biostatistics at UCLA.  She is the creator of the 
health state analysis technique and performed the cluster analysis for this study.  I thank 
you for your dedication over the entire course of this project and for providing statistical 
guidance along the way.  
 
I would like to thank my dear friend, Rebecca Lessem, a newly minted economist, 
who taught me STATA through the course of this project.  I cannot imagine anyone else 
who would have so willingly and tirelessly provided answers to all of my questions.  And 
again, I hope there will be many joint projects in our future.  
 
And finally I would like to thank Joern Putschke, for his patience and willingness 






Table of Contents   
 
Introduction ............................................................................................................................... 5 
Comparative effectiveness research today ............................................................................ 5 
A need for CEA studies of antipsychotics ............................................................................ 6 
How can CEA be more useful to clinical care? .................................................................. 13 
Need for new methods – health state analysis as an alternative approach .......................... 14 
Statement of aims and hypotheses .......................................................................................... 16 
Methods................................................................................................................................... 17 
Study design ........................................................................................................................ 17 
Measures.............................................................................................................................. 18 
Analyses .............................................................................................................................. 19 
Results ..................................................................................................................................... 22 
Sample Characteristics ........................................................................................................ 22 
Generating clusters .............................................................................................................. 22 
Concurrent Validation ......................................................................................................... 26 
Discussion ............................................................................................................................... 30 
Conclusion .............................................................................................................................. 39 
References ............................................................................................................................... 41 












Comparative effectiveness research today 
With the advent of many new treatments for psychiatric illnesses in the last fifty 
years, there has also been greater uncertainty about the relative effectiveness amongst 
treatments and the impact on a patient’s overall well-being. Comparative effectiveness 
research is potentially a powerful approach to improve quality of care and outcomes.  
With the passing of the American Recovery and Reinvestment Act of 2009, policy 
makers not only acknowledged its importance, but also allocated $1.1 billion to support 
new research and to create the Federal Coordinating Council for Comparative 
Effectiveness Research, an  organization to oversee its development (1).  
 
In 2007, the Institute of Medicine defined comparative effectiveness as the 
“comparison of one diagnostic or treatment option to one or more others” and others have 
defined it as the study of risks and harms associated with alternative options of health 
care and their impact on patients (2) (1). Comparative effectiveness studies have been a 
recent focus of research trials because of their potential to improve clinical care.  
However, the IOM has estimated that only half of the treatments that are considered 
standard of care have shown to be clinically effective in research trials and that the 
degree to which one treatment is more effective than another is in most cases unclear due 
to the lack of evidence (3).  The roots of this problem may lie deep in the US healthcare 





profile and effectiveness of new treatments as compared to placebo but does not typically 
require comparisons to be made with previously approved alternatives.  There is 
increasing clinical research comparing treatments but it is still recognized that there is not 
enough comparative research that can be directly clinically relevant (4). 
 
A need for CEA studies of antipsychotics 
Comparative effectiveness research may be particularly important in evaluating 
treatments for schizophrenia. Since the discovery of chlorpromazine in the late 1950’s, 
there has been an explosion of new antipsychotic medications on the market.  In 2007, 
there were over sixty approved antipsychotics worldwide (5). These medications are 
usually divided into two categories, first generation antipsychotics, including 
chlorpromazine, were those discovered prior to clozapine. In the 1980’s, reports were 
published about clozapine indicating unprecedented efficacy in treating refractory 
schizophrenia (6). All drugs discovered after its release was marketed as a new and 
distinctly superior category with fewer extrapyramidal symptoms and were labeled 
atypical or second generation antipsychotics (SGA’s).  
 
Initially it was thought that the SGA’s would be at least as effective in treating the 
positive symptoms of schizophrenia (hallucinations, delusional thinking, and thought 
disorganization), but would result in fewer side effects.  In addition, SGA’s were thought 





cognitive impairments and mood symptoms.  Based on these hopes, large professional 
bodies around the world including the American Psychiatric Association, the World 
Psychiatric Association, the United Kingdom’s National Institute for Health and Clinical 
Excellence, and the Texas Medication Algorithm Project recommended the newer 
medications in favor of the old (7) (8) (9) (10).  Some thought the SGA’s would render 
FGA’s obsolete (11).  
 
Subsequently, use of SGA’s have soared along with costs.  In 1994, the annual 
expenditures on antipsychotic medications in the U.S. was $1.4 billion and less than 5% 
of schizophrenic patients received SGA’s (12). Ten years later, 90% of patients received 
SGA’s and the annual expenditure totaled over $10 billion, with 70% paid by the U.S 
government through Medicaid (12). A similar story unfolded globally. Global 
expenditures on antipsychotic medications increased from $0.5 billion annually in the 
1990’s to more than $15 billion annually a decade later (13).  This increase was driven by 
use of SGA’s which cost 5-30 times more than FGAs.  Such costs could be justified if 
patients experienced significant symptom reduction and overall improvement in quality 
of life, but there is increasing skepticism about overall benefit.  Such uncertainty has led 
to a growing literature of systematic reviews and large scale clinical trials comparing 
effectiveness of antipsychotic medications.  
 
One of the first comprehensive systematic reviews was published by Geddes et al. 





Dec. 1998 comparing SGA’s (amisulpride, clozapine, olanzapine, quetiapine, risperidone, 
and sertindole) with FGA’s (most commonly haloperidol or chlorpromazine). Outcome 
measures included symptom measures and side effects. The study concluded that SGA’s 
were equally effective as a group and were no more effective than FGA’s when they 
controlled for higher than recommended doses of FGA’s in trials.  SGA’s still showed a 
moderate benefit in EPS symptoms, but there were no significant difference in dropout 
rates.  
 
 In contrast, a review published by Davis et al in 2003 concluded that SGAs were 
not a homogenous group in terms of effectiveness. That analysis included 142 
randomized controlled trials (published and unpublished data) up to May 2002 comparing 
ten SGA’s with FGA’s in patients with schizophrenia or schizoaffective disorder (15). 
The main outcome measure was symptom scores. The study concluded that four SGA’s 
(clozapine, amisulpride, risperidone, and olanzapine) were significantly more effective 
than FGA’s. The remaining SGA’s (aripiprazole, quetiapine, remoxipride, sertindole, and 
ziprasidone) were no more effective than FGA’s.  And unlike the Geddes et al. study, 
they found no evidence that the dose of FGAs affected the results.  
 
 Leucht and colleagues published the most recent review in 2009 comparing nine 
SGA’s with FGA’s on a variety of outcome measures, including symptoms, relapse rates, 
quality of life, EPS, weight gain and sedation (16).  Their review included 150 doubled 





highlighted in the Davis et al review (amisulpride, olanzapine, clozapine, and 
risperidone) were significantly more effective in treating both positive and negative 
symptoms with small to medium effect sizes and that aripiprazole, quetiapine, sertindole, 
ziprasidone, and zotepine were no more effective than FGA’s. In addition, SGA’s 
resulted in fewer EPS symptoms compared to haloperidol even at low doses, but the 
difference in EPS compared with less potent FGA’s was less clear. However, SGA’s 
(except for aripiprazole and ziprasidone) were associated with greater weight gain. They 
also concluded that few studies included data on quality of life and relapse rates. Leucht 
and colleagues also compared the results of their review with the others reported here as 
well as the Cochrane Reviews and concluded that all of the reviews demonstrated that 
amisulpride, clozapine, olanzapine and risperidone were superior to FGAs but for the 
other SGAs, there were no significant differences  (17) (16).  
 
The need for more objective and definitive evidence comparing effectiveness of 
different antipsychotics on the market also led to two large scale government sponsored 
multi-site trials on the long term effectiveness of medications to treat schizophrenia.  The 
Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) 
from the United Kingdom was a large (N=227) randomized clinical trial with a study 
design that mimicked real world prescribing practice. Clinicians were allowed to 
prescribe any SGA (excluding clozapine in the first arm of the study) and any FGA 
medication and both patients and clinicians were not blind to treatment assignment.  This 





significant advantage over FGAs after one year on measures of quality of life, symptoms, 
discontinuation, or side effects.  
 
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for 
schizophrenia was sponsored by the National Institute of Mental Health and conducted 
between 2001 and 2004. 1460 patients were followed for up to 18 months at 57 sites in 
the U.S and clinicians and patients were blinded to treatment assignment (18). CATIE 
compared the effectiveness of one first generation antipsychotic, perphenazine, with the 
four second generation antipsychotics available on the market at the time. Primary 
CATIE results found olanzapine to be associated with significantly longer time to 
discontinuation compared to quetiapine and risperidone but the difference was not 
significant in the perphenazine comparison. Time to all cause treatment discontinuation 
was significantly longer for clozapine in a treatment resisitant arm of the study compared 
to quetiapine and risperidone but not to olanzapine. And the overall discontinuation rate 
was high – 74% of patients discontinued their study medication before the end of trial at 
18 months. There were no significant advantages of second generation antipsychotics 
over perphenazine on symptoms, neurologic side effects, quality of life, employment, or 
neurophsychological functioning (19). Perphenazine was less costly by $300-500 per 
month compared to all SGA’s when accounting for medication costs and costs of health 






These reviews and clinical trials have been some of the largest to date, but they 
have not been without criticism.  More than 80% of the studies included in Leucht et al.’s 
meta analysis had a study period of 12 weeks or less, even though long term treatment of 
schizophrenic patients is needed to prevent relapse. Moreover, most of the trials included 
in the analysis are from early drug studies sponsored by pharmaceutical companies, 
which can skew the evidence in favor of those drugs over comparisons (21).  In addition 
the choice of comparison drugs in 95 out of 150 of Leucht’s analysis was haloperidol, a 
high potency FGA. Few studies chose medium potency drugs, such as perphenazine, 
which is thought to be associated with lower rates of EPS (22).  
 
Although it was hoped that results from these two large scale studies would 
provide conclusive answers, the results actually fueled more debate.  On one side, led by 
the primary investigators of the studies, the results were interpreted to suggest that SGA’s 
confer no additional clinical benefit over FGA’s.  On the other side, the argument is that 
the study methodologies were flawed and caution should be used in applying the results. 
Critics of the CATIE study point to several components.  In particular, they question the 
results indicating no difference in tardive dyskinesia (TD) across the medications.  In the 
CATIE trial, patients with tardive dyskinesia (about 15% of the sample) were excluded 
from being randomly assigned to perphenazine because it was generally thought in 2000 
by an expert panel that patients with TD should not be exposed to any FGA (23). Critics 
say this exclusion may have biased the samples so that those assigned to perphenazine 





investigators have pointed out that this issue was already addressed in the study design 
and analysis.  In the analysis, perphenazine patients were only compared to equivalent 
patients who did not have tardive dyskinesia at baseline.   
 
Although there were some differences between the results of CATIE and 
CUtLASS and those of the meta analyses, overall, the evidence suggests that FGA’s and 
SGA’s are not homogenous groups of medications and that each drug should be judged 
on its own efficacy and risk of side effects. Furthermore, with the results of such large 
scale multi-site government sponsored studies, there is also enough evidence to suggest 
that SGA’s as a group are no more effective than FGA’s, even though the debate will still 
likely continue. And as more is learned about the mechanisms of SGA’s, it is apparent 
that the mechanisms of drugs in this category differ significantly from one another. For 
example, it was thought that the property of blocking serotonin receptors accounts for 
their improved efficacy, but many of the most potent serotonin blockers are not more 
efficacious and amisulpride, which is not a serotonin blocker, is more effective than 
many other SGA’s (15).   
 
Yet, as some recent studies have shown, the knowledge gained from these large 
scale, carefully designed trials is not being disseminated widely to clinicians and is not 
having widespread impact on prescribing practices. A European survey of psychiatric 
trainees show that 96% of trainees prefer “atypical” antipsychotics for the acute treatment 





choices (24).  Side effect profile (21%) and cost (3%) played less of a role. Thus, it is still 
the case that many clinicians reach first for SGA’s for schizophrenia under the 
assumption that the drugs are more effective and have reduced side effects 
How can CEA be more useful to clinical care? 
One barrier in disseminating information from comparative effectiveness studies 
may be that the results are not always directly applicable to treatment selection for a 
specific patient with a complex clinical profile.  Clinical trials often incorporate methods 
such as subgroup analysis to look for effects that may pertain to specific patient 
populations, but such analysis is often not comprehensive and there are statistical 
challenges in their interpretation (1). However, even the most well designed clinical trials 
often fail to provide conclusions that can guide the crucial question of “what is the best 
treatment for this particular patient?”  
 
Outcomes of trials are usually reported using dimensional scales and comparisons 
are made using averages along dimensions of health including symptoms, side effects, 
and overall quality of life. This approach cannot capture important and complex 
relationships between different dimensions of health (25). And in clinical practice, 
treaters must routinely assess the relative benefit of symptoms and side effects as they 
emerge in multidimensional health states.  Comparative effectiveness research has been 
urged to develop methods to provide insight into overall clinical impact of medications 
because an individual patient can experience both benefit and harm from a given 






Need for new methods – health state analysis as an alternative approach 
Health state modeling is an analytic method that could potentially improve the 
practical value of comparative effectiveness research.  In this data driven approach, 
cluster analysis is used to classify patients.  Cluster analysis is a way of dividing data into 
meaningful or useful groups by capturing the natural structure of the data.  This technique 
is widely used in many fields including psychology, biology, statistics, pattern 
recognition, machine learning and data mining (27).  
 
Measurements at particular points in time can then be grouped into discrete multi-
dimensional health states such that patients in a given state are as similar as possible over 
several dimensions of symptoms and side effects. Clinically relevant change can then be 
measured as the probability of moving individuals from one health state to another rather 
than the traditional approach of measuring net increase or decrease over time on multiple 
preset scales. One can then compare randomized treatments by the differing probabilities 
of causing desirable transitions. For example, patients in two treatment groups can have 
similar levels of overall health, but one treatment increase the likelihood that patients 
have severe symptoms and few side effects while the other group leads to  severe side 
effects but few symptoms. Health state modeling could clearly distinguish between these 






Health state modeling has the additional benefit of providing a simple way to 
estimate long run outcomes using data from studies of a finite duration using Markov 
chain theory.   The transition probability from one health state to another can be 
accumulated over several time periods and across the entire patient sample to determine 
the distribution of patients in each health state at equilibrium with different treatments 
(28). These long run health states can be used to estimate health related utility levels or 
Quality Adjusted Life Years for use in cost-effectiveness or cost benefit analysis (29).  
 
This method has recently been used to compare outcomes of patient populations 
from different mental health programs in a paper by James et al (30).  In this study, they 
compare the health state modeling approach to a conventional mixed effects regression 
model in the analysis of longitudinal data of patients treated at a Veterans Affairs (VA) 
medical center versus patients treated at a Community Mental Health Center (CMHC).  
Although both methods produced similar conclusions – patients treated at the CMHC 
were more stable over time compared to VA treated patients, the health state analysis 
gave additional insight into which subgroups of the VA population were developing more 
severe symptoms. The analysis showed that patients in the best and worst health states 
changed little over time, but patients with mild symptoms with hallucinations and 
patients with severe positive and negative symptoms were the most likely to deteriorate.  
 
In another recent clinical trial, health state analysis was used to compare 





analysis was conducted of a randomized controlled trial comparing haloperidol and 
clozpaine in a hospitalized VA patient population. The health state model consisted of 
clusters with different symptom and side effect profiles. The study concluded that 
clozapine, compared to haloperidol, differentially increased the proportion of patients 
with mild symptoms and decreased the proportion of patients with severe positive 
symptoms, but the proportion of patients with negative symptoms stayed relatively 
constant over time.  And projecting long run outcomes and health costs using a Markov 
model, the study authors conclude that clozapine is more cost effective compared to 
haloperidol.  
 
In this study, we apply health state modeling as a secondary analysis of data from 
the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia 
trial. We use the primary data from this large study, which tried to represent a real world 
cohort of patients through its broad inclusion and exclusion criteria. Although the original 
analyses have provided insight into treatment effects on specific dimensions of health, the 
overall impact of medications remains ambiguous.   In this study, we re-analyze the data 
from CATIE using a health state approach. 
Statement of aims and hypotheses 
Aim 1 
Determine if health state analysis can potentially provide a richer picture of the clinical 






Health state analysis results in additional insights into the clinical and quality of life 
characteristics of patients compared to traditional dimensional approaches. 
Aim 2 
Apply health state analysis to compare the impact of various common antipsychotic 
medications on the health state outcomes of patients.  
Hypothesis 2 
There is no difference in the distribution of health states of patients across medications 




CATIE was conducted between January 2001 and December 2004 at 56 U.S. 
sites. The study was designed to compare effectiveness and cost-effectiveness of one first 
generation antipsychotic, perphenazine and the second generation antipsychotics 
olanzapine, quietiapine, risperidone and ziprasidone.  Details of the study and exclusion 
criteria have been reported elsewhere (31) (32). An algorithm assigned patients to a series 
of treatment phases. In phase 1, patient were assigned to medications under double-blind 
conditions and were followed up to 18 months or until treatment was discontinued for 
any reason.  Patients with tardive dyskinesia (15% of the sample) were excluded from the 





baseline were excluded from our analyses. Patients who discontinued the first medication 
they were assigned were invited to start another second-generation antipsychotic and 
open treatment was offered to patients who refused the second random assignment or 
who failed the second randomization. In the present analysis, we used a subset of data on 
patients treated with perphenazine, olanzapine, quetiapine and risperidone because 
ziprasidone was introduced after much of the sample had been recruited. 
Measures 
The data consisted of symptom measuring instruments including the Positive and 
Negative Syndrome Scale (33). The PANSS has 3 subsections: positive symptoms such 
as hallucinations and delusions, negative symptoms such as blunted affect, and general 
emotional disturbance such as anxiety and depression. The Calgary Depression Symptom 
Scale for Schizophrenia (34) further assesses specific neurovegatative and subjective 
aspects of depression including sleep, suicidality, and hopelessness.  In this analysis, we 
used summed scores from the subsections of the PANSS and the total Calgary score. 
Extrapyramidal side effects were assessed using the Abnormal Involuntary Movement 
Scale (35), the Barnes Akithesia Scale (36)and the Simpson-Angus Scale (37). The BMI 
was also included as a measure of metabolic side effects. With the exception of BMI, all 
of these instruments use Likert scales to measure symptom severity with higher scores 
indicating more severe symptoms.  
 
A broad selection of quality of life measures were used as validation measures for 





assessed as part of the original CATIE study and in this analysis, also serve as a measure 
of relative illness severity and psychosocial functioning associated with patients in each 
cluster. The measures include the Lehman Quality of Life summary item (38), a semi-
structured interview that assesses the overall life circumstances of patients with mental 
illness. The SF12 mental and physical subscales (39) are summary scores from a patient 
administered health related quality of life survey that has been widely used in many 
patient populations. The Heinrichs Carpenter Quality of Life Interview (40) was 
originally developed to assess the schizophrenia deficit syndrome and contains subscales 
measuring interpersonal relations, occupation, intrapsychic foundations (motivation, 
anhedonia, emotional interaction) and common objects and activities.  Finally, the Visual 
Analogue Scale is a patient’s self reported measure of overall health. Data were collected 
at baseline, 1, 3, 6, 9, 12, 15, and 18 months.  
 
Analyses  
We use K-means clustering on the standardized symptom and side effects 
measures  to obtain discrete health states. K-means is a partitioning algorithm that treats 
each observation in the dataset as an object with a location in multi-dimensional space 
defined by the characteristics that are measured (28).  The algorithm creates clusters of 
observations, where each cluster is defined by the patient members that have been 
assigned to it and by its centroid, or the center point of all the members in that cluster.  K-
means is an iterative algorithm that minimizes the sum of distances from each member in 





objects between clusters until the sum of distances has reached a global minimum. This 
results in non-empty non-overlapping clusters where members in each cluster are as close 
together as possible and where members in different clusters are as far apart as possible.   
 
The most important technical issue to consider in k-means cluster analysis is the 
selection of k, the number of clusters used.  K is a user defined value that can take on any 
integer value.  It is important to have as few clusters as possible for ease in interpreting 
results and to allow for enough subjects in each cluster for adequate statistical power.  
However, it is also important to have enough clusters so that patients who appear 
clinically different are not grouped into the same cluster. In this study, we use cluster 
profile plots as a visual tool to aid in selection of clusters. For each cluster, we plot the 
average score for each outcome score across all patients who belong to that cluster. We 
produce plots for different values of k and compare the patterns of plots to choose the 
greatest value of k where each cluster plot appears clinically distinct. We increase k as 
long as addition of clusters results in separation of cluster centers along at least one of the 
clinical axes.  This plot provides a picture of the average patient in each cluster and can 
also be used to provide a narrative description of these patients for purposes of utility 
measurement. In addition, we use quality of life measures as a way of validating and 
differentiating the severity of the health states.  
 
After choosing the number of clusters and removing patients with missing values, 





health state model.  We then used the health state model to compare outcomes across 
medications over time.  Specifically, we compared the proportion of patients in each 
health state at baseline and then at time 6 months across medications.  We examined the 
data cross-sectionally using chi-square tests of independence to determine if there were 
significant differences of health state patterns across the treatment groups at each time 
point.  
 
Next, we looked at long run differences in patterns of health states across 
medications.  Before applying Markov chain theory, we tested assumptions of stationarity 
of the data, to determine whether the transition probabilities from one state to another 
remain fixed over time. With data that remains stationary, one can calculate a stationary 
distribution, which is the fraction of patients residing in each health state modeled after 
many time periods.  
 
In this study, the initial clustering was performed by Dr. Catherine Sugar, a 
professor of biostatistics at UCLA who helped develop the health state technique.  The 
planning for the cluster analysis and selection of the optimum number of clusters were 
done in partnership with her and all data interpretation was performed by this paper’s 









Sample Characteristics  
Appendix 1 depicts the demographic and clinical characteristics of patients at the 
time of initial random assignment in this study.  The average age is 39.3. 74% of patients 
are male. 60.1% of patients are White and 60.6% of patients have never been married. 
The average burden of psychotic symptoms as measured by the PANSS total is 75.5.  
Patients on average are overweight, bordering on obese with BMI of 29.8.  The average 
monthly cost of all healthcare received is $2,299.   
 
Generating clusters 
In order to determine the optimal number of health states, all available 
observations with complete information on outcomes measures across all time points 
were used. By examining cross-tabulation tables and cluster profile plots using different 
number of clusters, it was determined that 5 clusters allowed for the greatest amount of 
differentiation amongst clinically meaningful clusters with the most parsimonious and 
interpretable set of clusters. Fig. 1 shows the cross-tabulation of cluster memberships 
between 4 and 5 cluster models.  In the figure, the rows represent the 4 cluster model and 
columns represent the 5 cluster model.  So the value in the first row, second column 
shows the number of people who were in cluster 1 in the 4 cluster model and cluster 2 in 
the 5 cluster model. The numbering of clusters is arbitrary in this case – for example, the 





model.  But patients in cluster 4 become distributed in clusters 4 and 5 in the 5 cluster 
model.  This indicates that most patients stay assigned to the same cluster, but that most 
of the patients in cluster 4 become reassigned to form clusters 4 and 5 in the 5 cluster 
model.   
 
Figure 1. Cross tabulation of 4 cluster and 5 cluster models. Values represent number of 
patients in each cluster under 4 cluster (rows) and 5 cluster (columns) models.  
  1 2 3 4 5 
Row 
Total  
1 196 92 0 0 0 288 
2 39 35 350 3 0 427 
3 3 13 55 172 0 243 
4 1 1 2 36 36 76 
Column 
Total  239 141 407 211 36 1034 
 
We examine cluster profile plots in order to determine the clinical differences 
between these clusters. Figure 2 shows 4 plots corresponding to each cluster in the 4 
cluster model. In each plot, the values shown are the re-centered scores calculated by 
subtracting the global mean from each score.  This allows one to compare values across 
all outcome measures for which the raw scales scores are measured on different scales.  
For example, cluster 1 is comprised of patients with low symptoms and low neurological 
side effects but high BMI scores. In the 5 cluster model, shown in Fig. 3, patients in 
cluster 1 have low symptoms, neurological side effects and low BMI scores, while cluster 
2 is a distinctly new cluster with low symptoms and side effects but strikingly high BMI.  





model has too few clusters to capture the clinical diversity in the patient sample.  The 
addition of clusters beyond 5 produced some additional distinctions in specific movement 
side effects, but the additional clusters come at the cost of interpretability, parsimony, and 
power for long run Markov analysis. 
 
Figure 2. Cluster plots for 4 cluster model with re-centered scores on Y axis and question 










Figure 3. Cluster plots for 5 cluster model with re-centered scores on Y axis and question 








Objective descriptions of the health states were then created from the mean scores 
of outcome measures of each health state and are shown in Table 1. For example, patients 
in cluster 4 in the 5 cluster model had high scores on all sections of the PANSS, highest 
depression scores, and high akithesia compared to other patients in the sample. In 
summary, the health states can be characterized as: 1) low symptoms and low side effects 
(LS+LSE) 2) low symptoms and obesity (LS+Ob) 3) high symptoms and low side effects 
(HS+LSE) 4) high symptoms with depression and akithesia (HS+Dp+Ak), and 5) 
moderate symptoms and high side effects (MS+HSE) 
 
Table 1. Mean (std. dev.) of 8 outcome measures across 5 clusters 






Gen.  Calgary AIMS Barnes 
Simpson 
Angus BMI 
1 2674 12.2 14.9 26.0 10.9 1.0 0.6 0.6 27.8 
    (3.6) (4.7) (5.2) (2.5) (2.1) (1.5) (1.1) (4.3) 
2 1310 14.6 16.9 30.7 12.2 1.0 0.6 0.7 40.6 
    (4.2) (4.6) (6.2) (3.3) (2.1) (1.4) (1.2) (5.7) 
3 2244 20.4 23.3 40.0 12.2 1.0 0.5 0.8 28.0 
    (5.0) (5.4) (6.9) (3.1) (2.2) (1.1) (1.2) (5.2) 
4 1095 20.2 21.4 43.3 19.4 2.9 4.2 1.9 30.3 
    (5.0) (5.8) (8.0) (4.5) (3.9) (2.9) (2.1) (7.1) 
5 852 16.8 20.0 35.6 12.0 10.5 2.8 3.8 29.2 
    (5.2) (5.8) (8.0) (3.1) (5.8) (2.9) (3.1) (5.8) 
 
Concurrent Validation 
In order to assess the differences in quality of life and overall psychosocial 





measures and report the mean values for each cluster in Table 2. We use these scores as 
an additional validation step in the choice of clusters. Patients in LS+LSE have highest 
(least symptomatic) mean scores across all validation measures which is consistent with 
the cluster characteristics of having the lowest symptoms and side effects.  Patients in 
cluster 4 (HS+Dp+Ak) have the lowest (worst) scores on all validation measures, 
consistent with the high burden of symptoms and side effects in this group.  
 
Table 2. Mean (std. dev.) of quality of life validation variables across 5 clusters 
  Clusters VAS¹ QOL31² HCTOT³ PCS12⁴ MCS12⁵ 
1 LS+LSE 73.4 4.8 3.3 50.9 46.3 
    (21.2) (1.2) (1.1) (8.5) (10.2) 
2 LS+Ob 68.2 4.6 3.0 46.7 43.5 
    (22.3) (1.3) (1.0) (10.1) (10.6) 
3 HS+LSE 64.1 4.3 2.4 49.6 41.4 
    (25.4) (1.3) (1.0) (9.3) (11.1) 
4 HS+Dp+Ak 47.1 3.6 2.3 45.0 32.1 
    (25.2) (1.3) (0.9) (11.3) (9.9) 
5 MS+HSE 66.3 4.6 2.6 48.2 43.8 
    (24.0) (1.3) (1.0) (9.6) (10.1) 
¹VAS: Visual Analog Scale (1-100) 
²QOL31: Lehman Quality of Life (1-7) 
³HCTOT: Heinrichs Carpenter Scale (0-6) 
⁴PCS12: SF-12 physical health summary scale (0-100) 
⁵MCS12: SF-12 mental health summary scale (0-100) 
 
We used the 5 cluster health state model in a cross sectional analysis to compare 
6-month outcomes across the four medications, perphenazine, olanzapine, risperidone 
and quetiapine. We performed intent to treat analysis, but similar to the original CATIE 





randomization from randomization to all of these drugs because those patients were 
excluded from the perphenazine arm of the trial. Chi square tests of independence 
between medication and health state at baseline showed no statistical difference (p = 
0.19) at baseline across the medications.  At 6 months, there was significant difference 
(p=0.0090) in the distribution of patients across health states for the 4 medications.  
Pairwise comparisons are performed between each pair of medications at 6 months (with 
6 pairs in total). Chi squared test was significant only for perphenazine vs. risperidone  (p 
= 0.012 < α of 0.025 with Hochberg false discovery rate correction) and for olanzapine 
vs. risperidone  (p= 0.0010 < α of 0.05) but not for any other pairwise comparisons (41). 
 
To assess specific differences in cluster distribution, we calculated the percent of 
patients in each health state at baseline and then at 6 months, shown in Table 3.  At 
baseline, 19.7% of patients were in the worst health state, HS+Dp+Ak, and the health 
state HS+LSE had the largest percentage of patients (over 38.9%). At 6 months, there 
was an across the board decrease in patients in the worst health state (HS+Dp+Ak), with 
the greatest decreases in the pherphenazine group (9.2% decrease) and olanzapine (11.1% 
decrease) groups compared to risperidone (4.7% decrease) and quetiapine (6.7% 
decrease) as seen in Table 4. There was a large increase in the best health state (LS+LSE) 
for patients taking perphenazine (15.0%), olanzapine (18.5%) and quetiapine (12.0%) but 
less for patients taking risperidone (4.5%).  Patients in MS+HSE comprised the smallest 








Table 3. Percentage of patients in each cluster at baseline and 6 months 





1 LS+LSE 24% 36% 12% 
2 LS+Ob 14% 19% 5% 
3 HS+LSE 39% 27% -12% 
4 HS+Dp+Ak 20% 13% -7% 
5 MS+HSE 4% 6% 2% 
 
Table 4. Percentage of patients in each cluster at baseline and 6 months across 
medications 


















1 24% 39% 15% 26% 45% 19% 19% 24% 4% 23% 35% 12% 
2 15% 19% 4% 10% 14% 4% 15% 19% 4% 14% 23% 9% 
3 38% 29% -9% 37% 23% -14% 42% 35% -7% 41% 24% -17% 
4 17% 8% -9% 24% 13% -11% 21% 16% -5% 19% 12% -7% 
5 6% 6% 0% 3% 6% 3% 3% 6% 3% 3% 6% 3% 
 
 
 Increases in the health state LS+Ob were similar across perphenazine (3.92%), 
olanzapine (3.83%) and risperidone (4.40%) groups but were higher in the quetiapine 
group (9.19%).  Within the LS+Ob group, the average BMI of the olanzapine group 
increased by 2.23%, while the BMI of all other medication groups decreased. Since 
olanzapine was associated with greater weight gain in the original analysis (31), we 
further examined continuous measures of BMI and found  the difference in BMI from 6 





2.64) and smallest for perphenazine (mean -0.077, std. dev. 2.35). Thus changes in 
obesity were not well captured by our clusters. 
 
In this analysis, 34% of patients were re-randomized into a different arm of the 
study or dropped out before 6 months. We compared the characteristics patients who 
stayed on the original medication at 6 months and those who did not.  There was no 
significant difference on any characteristic and a MANOVA performed on the 5 quality 
of life variables was not significant between the two groups (p = 0.52). Further analysis 
of the phase 1 only sample (excluding observations after discontinuation of the initially 
assigned drug) showed that Chi square comparisons across the 4 medications and 
between any medication and perphenazine was not significant (p = 0.19 across all 4 
medications).  Likewise, Chi square comparison at 6 months was not significant across 
all medications (p = 0.11).  Comparisons between pairs of medications indicate only 
olanzapine vs. risperidone was significant (p = 0.043 < α of 0.05 with Hochberg 
correction). As expected, when examining only the phase 1 sample, there was a greater 
increase in the best health state (LS+LSE, 15.9%) and greater decrease in the worst health 
state (HS+Dp+Ak, 9.7%). The change in the LS+Ob cluster remains very similar 5.1% 
compared to 5.0% in the entire sample.  
Discussion 
The goal of this study was to determine if the application of health state analysis 





of a set of widely used pharmacological treatments.  To this end, we demonstrated that 
health state approach can provide a richer picture of the overall clinical status of patients 
than simple linear measures and can document transitions between states that can be 
followed over time and compared between treatments.  This approach could potentially 
help researchers better communicate their findings to clinicians. It may also provide a 
better description to patients of their expected symptom and side effect profiles if they 
choose to remain adherent to a given treatment. We have also shown how health state 
analysis can be used to account for overall changes in quality of life.   
 
This is the first comparative effectiveness study, to our knowledge, that applies 
health state analysis to clinical trial data of several commonly used antipsychotic 
medications for the treatment of schizophrenia and is one of a small group of studies 
employing health state analysis in general.  Although the results of our study generally 
confirm  the results of original CATIE analyses that employed traditional methods to 
compare outcomes using linear dimensions of health, this study provides additional 
support for the view that second generation antipsychotic medications provide no 
additional benefit over the first generation antipsychotic used in this trial.  
 
An initial aim of this study was to determine if health state analysis could be 
applied to data from a large clinical trial to identify simple and clinically meaningful 
representations of a complex patient population with schizophrenia.  To this end, we 





symptom measures and 4 side effect measures. Assuming 8 total dimensions of health 
with a minimum of 3 levels in each dimension, a traditional full factorial design 
describing the same population would have required at least 24 health states, even though 
many of those states may not be occupied. Such large number of states would have 
required a much larger sample of patients in order to obtain meaningful results.  
 
With health state analysis, the selection of clusters is purely data driven by an 
algorithm that minimizes within group differences and maximizes between group 
differences.  However, one can easily judge if the individual health states are distinctly 
clinically meaningful.  In this analysis, the 5 cluster model created health states with 
average values on the symptom and side effect scales that could be easily described with 
distinct clinical characteristics.  Although, the description of health states using this 
method introduces a level of clinically informed judgment, the benefit of having such a 
parsimonious model allowing further analysis outweighs it.  Furthermore, we conducted 
additional validation analyses using a panel of commonly used quality of life measures.  
We show that the LS+LSE health state is associated with the highest scores and highest 
quality of life, which is intuitive clinically. Furthermore, the HS+Dp+Ak health state is 
associated with the lowest scores on all four validation scales, with lower scores than 
other health states (MS+HSE) which also have high symptom and side effect burdens. 
The other three health states have varying scores on the different validation measures 





relatively low scores on the physical component of the SF12 quality of life instrument, 
but a comparable score to MS+HSE on the QOL31, an overall measure of quality of life.  
 
The next aim of our study was to determine if health state analysis could 
potentially provide more information than traditional dimensional comparisons.  In 
studies using these traditional methods, outcomes are usually reported as average changes 
on an outcome measure along each dimension separately.  For example, a medication 
could result in an average improvement of 10% on symptom measures and also result in 
5% increase in side effects.  However, it is difficult to determine if the same patients are 
experiencing both symptom improvement and side effects or if one subpopulation is 
experiencing the majority of clinical benefit and another population is experiencing 
predominant increase in side effects.  In our analysis, the health states encompass both 
symptoms and side effects so we can easily assess the overall impact of treatment over 
time.  
 
 In this analysis, we showed that at baseline, the majority of patients were in 
health states with a high symptom and side effect burden (39% in HS+LSE and 20% in 
HS +Dp+Ak).  However, there was also a significant proportion of patients at baseline in 
the LS+LSE health state.  Over 6 months of treatment, averaging transitions across all 
study medications, there was a large increase in the LS+ LSE health state and a large 
decrease in the HS+LSE and HS+Dp+Ak indicating that in general, the same patients 





However, there was also a sizable increase in the proportion of patients in the low 
symptoms and high obesity (BMI) health state (5% increase) in the course of 6 months.  
And at 6 months, over a third of patients still experienced moderate to high levels of 
symptoms and side effects. Interestingly, the proportion of patients in the MS+HSE state 
remained relatively low and constant over the 6 months (3.5% increase to 5.8% at 6 
months).  This health state may have represented a small group of patients who were 
treatment resistant or were predisposed to experience a high level of side effects.   
 
The final aim of this study was to determine whether there were differences in the 
distribution of changes in health states across different medications.  Despite a group of 
very large meta analyses indicating that only a few SGA’s potentially provide better 
outcomes and several large multi-site national trials indicating that SGA’s do not provide 
better outcomes over the FGA’s used in those trials, there is still considerable controversy 
about the relative effectiveness of the newer SGA medications.  In addition, many 
clinicians still believe SGA’s are more efficacious in general, although those opinions are 
likely based as much on intensive marketing as on knowledge of outcomes research 
results (24).  Thus, there is a need for additional comparative effectiveness research that 
could provide evidence to further guide clinicians in their choice of treatments. 
 
In our intent to treat analysis, we showed that the distribution of patients across 
clusters at 6 months was significantly different across the four medications (p = 0.009).  





distributions were significantly different only between perphenazine and risperidone (p = 
0.012 < α of 0.025 after Hochberg correction) and between olanzapine and risperidone (p 
= 0.001 < α of 0.05 after Hochberg correction).  Comparing the percentage of patients in 
the five clusters at 6 months, it was clear that both perphenazine and olanzapine resulted 
in a larger increase in the LS+LSE (best) health state and a larger decrease in the 
HS+Dp+Ak (worst) health state in comparison to risperidone.  Risperidone was also 
associated with the smallest decrease in the HS+LSE health.  Risperidone resulted in 
similar changes in the LS+Ob and MS+HSE health states so that overall, it appeared that 
perphenazine and olanzapine were significantly superior medications to risperidone, at 
least at the dosages used in this double blind trial.  There were no significant differences 
between any other pair of medications.    
 
Compared to recent large meta analyses, our results align most closely with that 
of Geddes and colleagues (14) who found  that SGA’s as a group were no more effective 
than FGA’s.  However, in contrast to our analysis, they also found that SGA’s show a 
moderate benefit in EPS symptoms.  The reviews by both Davis and colleagues (15)and 
Leucht and colleagues(16) both concluded that olanzapine and risperidone were 
significantly more effective than FGA’s and were also associated with fewer EPS, 
although the Leucht review noted that the evidence was predominantly based on 
comparisons with the high potency drug haloperidol, and were far less clear for 
comparisons with low or intermediate potency FGA’s.  The use of perphenazine, an 





In our analysis, perphenazine was associated with a similar decrease in HS+Dp+Ak and 
MS+HSE, the two health states with high movement side effects, compared with the 
three SGA’s in this study.  In addition, as acknowledged by Leucht and colleagues, the 
effectiveness design of the CATIE and CUtLASS studies was quite different from the 
efficacy designs used by most of the studies included in the meta analyses, and thus more 
informative about real-world practice (16). Most previous studies, like many of those 
used in the meta analyses addressed safety and efficacy whereas the two large scale 
clinical trials focused more on real world effectiveness by including diverse sites and 
allowing far broader inclusion and fewer exclusion criteria.   
 
Unsurprisingly, our results are closely aligned with those of the original CATIE 
analysis.  The primary results indicated that olanzapine was associated with a longer time 
to discontinuation compared to risperidone and quetiapine, but not compared to 
perphenazine (31).  There were no significant differences between any SGA and 
perphenazine on measures of symptoms, side effects, or quality of life.  Although the 
results indicated similar conclusions overall, there are some differences.  For example, 
our results showed that perphenazine and olanzapine were associated with a significantly 
different distribution of health states compared to risperidone.  Risperidone was 
associated with the smallest changes in LS+LSE, HS+Ak+Dp, and HS+LSE.  These 
changes suggested that risperidone was associated with the lowest probability of 
transitioning a patient to an improved health state. This data could potentially provide 





may be associated with some improvements as seen on average changes on various 
outcomes measures, our results suggested that the medication was associated with the 
lowest probability of significant clinical improvement as defined by the health states in 
this study.   
 
An additional goal of this study was that health state analysis could be used to 
obtain long run predictions on the distribution of patients across health states under the 
different medications.  In order to obtain these predictions, we tested the data for the 
assumptions of Markov chain theory which requires that the data fit both the stationary 
criteria, where the transition probabilities from one state to another would remain fixed 
over time, and also the assumption that the transition probabilities could depend on 
nothing other than the previous health state.  However, since our data did not appear to 
meet these criteria, Markov analysis could not be conducted.  Specifically when 
evaluating data across the entire 18 month study period, it appeared that transition 
probabilities were dependent on more than just the previous health state.  We surmise that 
this finding is likely to reflect the high dropout rate over the course of 18 months during 
the CATIE trial.  In fact, over 74% of the patients discontinued their initial study 
medication prior to the end of the trial.   In order to test the impact of dropout on the 
results of our first 6 month analysis, we evaluated the sample for differences in clinical 
and demographic features between those who stopped their study medication at 6 months 
and those who stayed and found no significant differences in between the two groups.  





course of the 18 months and lended significant variability to the pattern of transition 
probability over time.  Thus, in this analysis we focused only on changes in health state 
over the first 6 months, a clinically meaningful interval, during which drop outs were 
limited.   
 
The health state approach as applied to the CATIE data has several limitations.  
First, the generation of clusters was completely data driven and was based on the data for 
the sample at hand.  As a result, the observed clusters may not be generalizable to other 
clinical samples. We used data from a large clinical trial designed to assess differences in 
effectiveness of medications under real world conditions.  Although the study had broad 
inclusion and exclusion criteria, the sample may still represent a subset of patients with 
chronic schizophrenia who may have failed previous treatments.  A second limitation was 
the challenge of applying statistical tests to the cluster distributions we obtained.  
Although we use chi square test to determine if the distribution of health states is the 
same for patients receiving different treatments, we must also analyze the percent of 
patients within the different health states to determine if one pattern of health states is 
preferable to another.  In addition, the health states themselves may not pick up on subtle 
differences in outcome.  For example, our results showed that  the changes in proportion 
of patients in LS+Ob was similar for patients treated with perphenazine, olanzapine and 
risperidone, but was higher for those in the quetiapine group.  However, we also found 
that the difference in BMI from baseline to 6 months was highest for olanzapine and was 





original CATIE trial results showing a greater increase in BMI for patients treated with 
olanzapine, suggest that there can be heterogeneity within a cluster that may mask some 
significant differences in outcome across treatment groups.  
 
This example also illustrates the challenge of directly comparing health state 
analysis with outcomes of traditional dimensional methods. Because health state analysis 
clusters patients along various dimensions of health, it can be challenging to compare the 
results to traditional methods that compare patients along single dimensions of health. 
Finally, with health state analysis, there is an element of judgment in determining the 
appropriate number of health states that balances detail against simplicity. In this 
analysis, the final selection of number of health states was strongly influenced by need 
for ease of interpretability and parsimony.   
 
Conclusion 
In this study, we show that health state analysis is a useful tool in the comparison 
of multiple treatments for a clinically complex illness such as schizophrenia.  It not only 
strengthens previous results, but can also provide additional insights into the differences 
in overall health outcomes of patients.  From our analysis, we conclude that SGA’s are 
not a homogenous group in terms of effectiveness.  And as a group, they are no more 
superior to perphenazine, an intermediate potency FGA, which is associated with a large 





now added to a growing body of work indicating that SGA’s as a group are not better 
than many FGA’s on symptoms and side effects taken as a whole.  The release of many 
new SGA’s in the last decade with strikingly similar mechanisms, symptom and side 
effect profiles may make it more challenging for clinicians to decide on the most 
appropriate treatment for patients.  However, with the nation’s rapidly rising healthcare 
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Clinical and demographic characteristics across medications of sample used for initial 
clustering*.  
Total Sample Olanzapine Perphenazine Quetiapine Risperidone
Mean/N %/SD Mean/N %/SD Mean/N %/SD Mean/N %/SD Mean/N %/SD
 N=1049 N=263 N=256 N=261 N=269
Age 39.3 10.9 39.36 10.56 39.97 11.06 39.15 10.88 38.78 11.05
Male 777 74.0% 190 72.2% 196 76.6% 192 73.5% 199 74.0%
Race/Ethnicity
White 631 60.1% 153 58.2% 151 59.0% 167 64.0% 160 59.5%
Black 368 35.1% 96 36.5% 90 35.1% 84 32.1% 98 36.4%
Hispanic 129 12.3% 37 14.1% 24 9.3% 39 14.9% 29 10.8%
Marital Status
Married 131 12.5% 30 11.4% 43 16.8% 27 10.3% 31 11.5%
Separated/        
Divorced 219 20.8% 61 23.2% 50 19.4% 55 20.9% 53 19.8%
Never 
Married 636 60.6% 159 60.4% 146 57.0% 167 64.0% 164 61.0%
PANSS Total 75.5 17.5 75.7 18.2 74.2 18.0 74.8 17.0 77.2 16.5
Positive 18.4 5.6 18.4 5.5 17.9 5.9 18.3 5.4 19.0 5.6
Negative 20.2 6.5 20.3 6.7 20.3 6.3 19.8 6.5 20.4 6.4
General 36.9 9.3 37.0 9.8 36.0 9.5 36.7 9.2 37.8 8.6
Depression 1.6 0.6 1.6 0.6 1.6 0.6 1.6 0.6 1.6 0.6
Side Effects
Simpson 
Angus 0.18 0.29 0.16 0.27 0.19 0.32 0.16 0.25 0.20 0.29
Barnes 0.47 0.84 0.58 0.97 0.43 0.79 0.46 0.76 0.47 0.81
AIMS 0.12 0.27 0.15 0.31 0.12 0.27 0.11 0.24 0.12 0.23
BMI 29.80 7.09 29.24 6.86 29.63 6.93 30.22 7.05 30.09 7.48
Health costs (previous month)
All 
medication $422 $325 $419 $344 $420 $314 $418 $331 $433 $313
Inpatient/   
Residential $1,512 $3,715 $1,828 $3,988 $1,127 $2,530 $1,442 $3,642 $1,636 $4,381
Outpatient $365 $935 $379 $864 $392 $1,173 $410 $1,066 $281 $513
Total $2,299 $3,831 $2,628 $4,078 $1,940 $2,811 $2,271 $3,813 $2,352 $4,389
* Data courtesy of Supplemental Table 1 of (42) 
 
